RUNX家族转录因子1在宫颈腺癌组织中的表达水平及其与患者预后的关系

doi:10.3969/j.issn.1004-616x.2025.03.003

摘要/Abstract

摘要： 目的：宫颈腺癌以其高侵袭性而显著不同于宫颈鳞状细胞癌，且对放疗的响应较低，导致患者预后不良和生存率较低。本研究旨在探讨RUNX家族转录因子1(RUNX1)在宫颈腺癌组织中的表达水平及其与患者预后的关系。方法：收集37例宫颈腺癌患者的肿瘤组织样本，通过免疫组织化学法检测肿瘤组织中RUNX1的表达水平，统计分析其表达水平与患者病理指标以及预后的相关性。利用人类蛋白质图谱(HPA)数据库分析RUNX1在宫颈腺癌组织中的蛋白表达水平。利用GSVA评分和TIMER2.0平台对癌症基因组图谱(TCGA)数据库中的相关宫颈腺癌数据集分别进行信号通路和免疫细胞浸润分析，初步揭示RUNX1在宫颈腺癌中的作用机制。结果：免疫组织化学检测结果与患者临床病理资料进行相关性分析显示，RUNX1蛋白在宫颈腺癌中的高表达与患者的总生存期和病理分期呈显著负相关(P<0.05)。对HPA数据库分析发现RUNX1蛋白在宫颈腺癌组织中的表达水平显著高于正常宫颈组织；通过分析 TCGA 数据库中的宫颈腺癌数据集，GSVA 评分分析显示 RUNX1 高表达主要富集的通路有有丝分裂纺锤体、Hedgehog通路、TGF-β通路、Wnt/β-catenin信号通路和p53通路；免疫细胞浸润分析显示，RUNX1表达与中性粒细胞浸润密切相关。结论：RUNX1在宫颈腺癌中高表达，且RUNX1高表达与患者不良预后显著相关，可能成为宫颈腺癌患者预后预测的潜在标志物。

关键词: 宫颈腺癌, RUNX1, 预后, 免疫细胞浸润

Abstract: OBJECTIVE： Cervical adenocarcinoma is markedly distinct from cervical squamous cell carcinoma due to its highly aggressive nature， lower response to radiotherapy， poor prognosis and reduced survival rates. This study aimed to investigate the expression level of RUNX1 in cervical adenocarcinoma tissues and its association with patient prognosis. METHODS： Tumor tissue samples from 37 cervical adenocarcinoma patients were collected. RUNX1 expression in tumor tissues was detected by immunohistochemistry (IHC)， and its correlation with clinicopathological parameters and prognosis was statistically analyzed. The Human Protein Atlas (HPA) database was used to analyze the protein expression level of RUNX1 in cervical adenocarcinoma tissues. Gene Set Variation Analysis (GSVA) scoring and the TIMER2.0 platform were utilized to perform signaling pathway enrichment and immune cell infiltration analyses， respectively， using cervical adenocarcinoma datasets from The Cancer Genome Atlas (TCGA) to preliminarily elucidate the mechanistic role of RUNX1 in cervical adenocarcinoma. RESULTS： Immunohistochemistry results demonstrated that RUNX1 expression in cervical adenocarcinoma showed significant differences correlated with patient prognosis and pathological stage (P<0.05). Patients in the RUNX1 high-expression group exhibited shorter overall survival and more advanced pathological stages. Analysis of the HPA database revealed that the protein expression level of RUNX1 was significantly higher than in normal cervical tissues. GSVA of cervical adenocarcinoma datasets from TCGA revealed that RUNX1 high expression was predominantly enriched in pathways including mitotic spindle assembly，Hedgehog signaling，TGF-β signaling，Wnt/β-catenin signaling， and p53 signaling. Immune cell infiltration analysis via TIMER2.0 indicated a significant correlation between RUNX1 expression and neutrophil infiltration. CONCLUSION： RUNX1 was found to be highly expressed in cervical adenocarcinoma and its overexpression was significantly associated with adverse prognosis，suggesting its potential as a prognostic biomarker for cervical adenocarcinoma patients.

Key words: cervical adenocarcinoma, RUNX1, prognosis, immune cell infiltration

中图分类号:

R737.33

郭艾, 黄宁, 张菁, 张媛媛, 安菊生, 刘梅. RUNX家族转录因子1在宫颈腺癌组织中的表达水平及其与患者预后的关系[J]. 癌变·畸变·突变, 2025, 37(3): 190-195.

GUO Ai, HUANG Ning, ZHANG Jing, ZHANG Yuanyuan, AN Jusheng, LIU Mei. Expression of RUNX family transcription factor 1 and its prognostic value in cervical adenocarcinomas[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2025, 37(3): 190-195.

参考文献

[1] ZHENG W N, JIN F Y, WANG F, et al. Analysis of eEF1A2 gene expression and copy number in cervical carcinoma[J]. Medicine, 2023, 102(2): e32559.
[2] ARBYN M, WEIDERPASS E, BRUNI L, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis[J]. Lancet Glob Health, 2020, 8(2): e191-e203.
[3] BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
[4] ADEGOKE O, KULASINGAM S, VIRNIG B. Cervical cancer trends in the United States: a 35-year population-based analysis[J]. J Womens Health, 2012, 21(10): 1031-1037.
[5] GUO F J, COFIE L E, BERENSON A B. Cervical cancer incidence in young U.S. females after human papillomavirus vaccine introduction[J]. Am J Prev Med, 2018, 55(2): 197-204.
[6] RERUCHA C M, CARO R J, WHEELER V L. Cervical cancer screening[J]. Am Fam Physician, 2018, 97(7): 441-448.
[7] BEDELL S L, GOLDSTEIN L S, GOLDSTEIN A R, et al. Cervical cancer screening: past, present, and future[J]. Sex Med Rev, 2020, 8(1): 28-37.
[8] SMITH A J B, BEAVIS A L, ROSITCH A F, et al. Disparities in diagnosis and treatment of cervical adenocarcinoma compared with squamous cell carcinoma: an analysis of the national cancer database, 2004-2017[J]. J Low Genit Tract Dis, 2023, 27(1): 29-34.
[9] HODGSON A, PARK K J. Cervical adenocarcinomas: a heterogeneous group of tumors with variable etiologies and clinical outcomes[J]. Arch Pathol Lab Med, 2019, 143(1): 34-46.
[10] VAN DYNE E A, HENLEY S J, SARAIYA M, et al. Trends in human papillomavirus-associated cancers-United States, 1999-2015[J]. MMWR Morb Mortal Wkly Rep, 2018, 67(33): 918-924.
[11] GIEN L T, BEAUCHEMIN M C, THOMAS G. Adenocarcinoma: a unique cervical cancer[J]. Gynecol Oncol, 2010, 116(1): 140- 146.
[12] RIDDELL A, MCBRIDE M, BRAUN T, et al. RUNX1: an emerging therapeutic target for cardiovascular disease[J]. Cardiovasc Res, 2020, 116(8): 1410-1423.
[13] TAHIROV T H, INOUE-BUNGO T, MORII H, et al. Structural analyses of DNA recognition by the AML1/Runx-1 Runt domain and its allosteric control by CBFbeta[J]. Cell, 2001, 104(5): 755-767.
[14] MIYOSHI H, SHIMIZU K, KOZU T, et al. T(8；21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1[J]. Proc Natl Acad Sci USA, 1991, 88(23): 10431-10434.
[15] LU C H, YANG Z Y, YU D Y, et al. RUNX1 regulates TGF-β induced migration and EMT in colorectal cancer[J]. Pathol Res Pract, 2020, 216(11): 153142.
[16] HÄNZELMANN S, CASTELO R, GUINNEY J. GSVA gene set variation analysis for microarray and RNA-seq data[J]. BMC Bioinformatics, 2013, 14: 7.
[17] LIBERZON A, BIRGER C, THORVALDSDÓTTIR H, et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection[J]. Cell Syst, 2015, 1(6): 417-425.
[18] LI T W, FU J X, ZENG Z X, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells[J]. Nucleic Acids Res, 2020, 48(W1): W509-W514.
[19] GULLUNI F, MARTINI M, DE SANTIS M C, et al. Mitotic spindle assembly and genomic stability in breast cancer require PI3K-C2α scaffolding function[J]. Cancer Cell, 2017, 32(4): 444-459.e7.
[20] SHEN D Y, XIA Y W, FU Y H, et al. Hedgehog pathway and cancer: a new area (Review)[J]. Oncol Rep, 2024, 52(3): 116.
[21] ZHAO M, MISHRA L, DENG C X. The role of TGF-β/SMAD4 signaling in cancer[J]. Int J Biol Sci, 2018, 14(2): 111-123.
[22] SONG P, GAO Z R, BAO Y G, et al. Wnt/β-catenin signaling pathway in carcinogenesis and cancer therapy[J]. J Hematol Oncol, 2024, 17(1): 46.
[23] HERNÁNDEZ BORRERO L J, EL-DEIRY W S. Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting[J]. Biochim Biophys Acta Rev Cancer, 2021, 1876(1): 188556.
[24] WANG Y L, WU W R, LIN P L, et al. The functions of PCNA in tumor stemness and invasion[J]. Int J Mol Sci, 2022, 23(10): 5679.
[25] NOVAK D, HÜSER L, ELTON J J, et al. SOX2 in development and cancer biology[J]. Semin Cancer Biol, 2020, 67(Pt 1): 74-82.
[26] LIN T C. RUNX1 and cancer[J]. Biochim Biophys Acta BBA Rev Cancer, 2022, 1877(3): 188715.
[27] LIEW P X, KUBES P. The neutrophil’s role during health and disease[J]. Physiol Rev, 2019, 99(2): 1223-1248.